IRB #

STUDY00017895

Title

Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage’s CIVO™ device in soft tissue sarcoma patients undergoing surgery.

Principal Investigator

Kenneth Gundle

Study Purpose

This study is investigating the microinjection of anti-cancer drugs followed by clinically-indicated surgical biopsy or tumor resection surgery.

Medical Condition(s)

Surgically resectable soft tissue sarcoma

Eligibility Criteria

18 years or older and surgically resectable soft tissue sarcoma

Age Range

18 - 90

Healthy Volunteers Needed

No

Duration of Participation

A total of two in-person visits – one for tumor microinjection and one for tumor resection – are expected for this study. Total duration of participation expected to be 28 days.

Minors Included

No

Contact

Samantha Wise
wisesama@ohsu.edu
503-418-1941

Knight Clinical Trials Office
trials@ohsu.edu

Sponsor

Presage Biosciences

Recruitment End

12/31/2020

Compensation Provided

No


Go Back